Core Insights - Genmab A/S will hold its 2025 R&D Update and ASH Data Review Meeting virtually on December 11, 2025, at 11:00 AM Eastern Time, which can be accessed via live webcast [1] - The meeting is not part of the official ASH Annual Meeting program [2] Company Overview - Genmab is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics, with over 25 years of experience in developing next-generation antibody technology platforms [3] - The company aims to transform the lives of individuals with cancer and other serious diseases by 2030 through its proprietary pipeline, which includes bispecific T-cell engagers and antibody-drug conjugates [3] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [4]

As filed with the U.S. Securities and Exchange Commission on November 28, 2025 Registration No. 333-291347 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abpro Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 87-1013956 (I.R.S. Employer Identificat ...

As filed with the U.S. Securities and Exchange Commission on November 7, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abpro Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) (Primary Standard Industrial Delaware 2834 87-1013956 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation or organization) Classification Code Number) 100 Summit Drive ...

As filed with the U.S. Securities and Exchange Commission on November 7, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Abpro Holdings, Inc. (Exact Name of Registrant as Specified in its Charter) (Primary Standard Industrial Delaware 2834 87-1013956 (I.R.S. Employer Identification No.) (State or other jurisdiction of incorporation or organization) Classification Code Number) 100 Summit Drive ...

Company Overview - Genmab A/S is an international biotechnology company focused on improving the lives of patients through innovative antibody therapeutics [2][3] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3] Upcoming Events - Genmab's CEO Jan Van de Winkel and CFO Anthony Pagano will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025, at 12:00 PM GMT [1] - A webcast of the event will be available on Genmab's website [1] Strategic Vision - By 2030, Genmab aims to transform the lives of individuals with cancer and other serious diseases through its innovative antibody medicines, referred to as "knock-your-socks-off" (KYSO) therapies [2]

Business Highlights - OmniAb has 104 active partners as of September 30, 2025 [13] - The company has 399 active programs as of September 30, 2025, a net addition of 36 programs year-to-date [16, 18] - There are 32 active clinical programs and approved products as of September 30, 2025 [26] - OmniAb is launching OmniUltra in December, a new technology for antibody and peptide therapeutics discovery [11, 41] Financial Performance - Q3 2025 total revenue was $22 million, compared to $42 million in Q3 2024 [65] - License and milestone revenue decreased to $06 million in Q3 2025 from $14 million in Q3 2024 [65] - Service revenue decreased to $12 million in Q3 2025 from $25 million in Q3 2024 [65] - Royalty revenue increased to $04 million in Q3 2025 from $03 million in Q3 2024 [65] - Research and Development expenses decreased to $104 million in Q3 2025 from $133 million in Q3 2024 [65] - Net loss was ($165) million in Q3 2025, compared to ($164) million in Q3 2024 [65] Financial Guidance - The company expects 2025 revenue to be in the range of $18 to $22 million [67] - The company expects 2025 operating expense to be in the range of $82 to $86 million [67]

Core Insights - Harbour BioMed reported significant financial growth in the first half of 2025, with total revenue of approximately US$101.3 million, representing a 327% increase year over year, and net profit reaching approximately US$73.0 million, a 51-fold increase compared to the same period in 2024 [4][5][25] Financial Performance - The company achieved a profit growth of more than fiftyfold year over year, indicating strong growth momentum [2] - Harbour BioMed's cash position improved to about US$320 million, a 92% increase since the end of the previous year [4] Product Pipeline and Development - Harbour Therapeutics, a sub-brand, is responsible for the development of the company's product pipeline in immunology and oncology, with several key clinical-stage projects making significant progress [6] - Key products in clinical stages include: - Batoclimab (HBM9161), a novel anti-FcRn monoclonal antibody, has completed Phase I to pivotal trials in China and has shown sustained efficacy and safety in treating gMG [7] - HBM9378, targeting TSLP for asthma and COPD, has received IND approval and is undergoing global Phase 2 trials [8][9] - Porustobart (HBM4003), a next-generation anti-CTLA-4 antibody, has shown positive efficacy and safety data in trials for advanced solid tumors [10] - HBM1020, targeting B7H7, has demonstrated excellent safety profiles in patients with advanced solid tumors [10] Strategic Collaborations - The company entered a global strategic collaboration with AstraZeneca to develop next-generation multi-specific antibodies, which includes a $105 million equity investment from AstraZeneca [16] - Harbour BioMed has signed several licensing and collaboration agreements, including partnerships with Windward Bio and Otsuka Pharmaceutical to advance the development of HBM9378 and HBM7020, respectively [17][12] Innovation and Technology - Harbour BioMed is leveraging its proprietary Harbour Mice® platform to develop next-generation biologics for CNS disorders and obesity treatment through its new venture Élancé Therapeutics [14][15] - The company continues to expand its technology platforms, including the launch of Hu-mAtrIx™, an AI-assisted drug discovery engine [22] Future Outlook - The achievements in the first half of 2025 position Harbour BioMed well for future growth, with plans to advance multiple clinical trials and expand its global collaboration network [25][27][28]

Company Overview - Genmab A/S is an international biotechnology company focused on improving patient lives through innovative antibody therapeutics [2][3] - Established in 1999 and headquartered in Copenhagen, Denmark, Genmab has a global presence across North America, Europe, and Asia Pacific [3] Upcoming Events - Genmab's CEO Jan Van de Winkel and CFO Anthony Pagano will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 7:45 AM EDT [1] Strategic Vision - By 2030, Genmab aims to transform the lives of patients with cancer and other serious diseases through its proprietary pipeline, which includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators [2]